Prelude Therapeutics annual operating expenses
2019
2020
2021
2022
2023
2024
2025
Prelude Therapeutics Operating Expenses Growth & History (PRLD)
Prelude Therapeutics's operating expenses was $116.7M for fiscal 2025.
View full Prelude Therapeutics company overviewPrelude Therapeutics annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $116.7M | −$30.0M | −20.45% |
| 2024 | 2024-12-31 | $146.7M | $14.4M | +10.91% |
| 2023 | 2023-12-31 | $132.3M | $8.7M | +7.07% |
| 2022 | 2022-12-31 | $123.5M | $9.8M | +8.62% |
| 2021 | 2021-12-31 | $113.7M | $55.0M | +93.55% |
| 2020 | 2020-12-31 | $58.8M | $30.7M | +109.05% |
| 2019 | 2019-12-31 | $28.1M | — | — |
Prelude Therapeutics quarterly operating expenses
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $21.2M | −$11.0M | −34.28% |
| Q1 2026 | 2026-03-31 | $18.8M | −$15.8M | −45.80% |
| Q4 2025 | 2025-12-31 | $23.0M | −$14.8M | −39.24% |
| Q3 2025 | 2025-09-30 | $26.9M | −$10.5M | −27.98% |
| Q2 2025 | 2025-06-30 | $32.2M | −$5.0M | −13.37% |
| Q1 2025 | 2025-03-31 | $34.6M | $263,000 | +0.77% |
| Q4 2024 | 2024-12-31 | $37.8M | $452,000 | +1.21% |
| Q3 2024 | 2024-09-30 | $37.4M | $4.0M | +11.95% |
| Q2 2024 | 2024-06-30 | $37.2M | $4.8M | +14.71% |
| Q1 2024 | 2024-03-31 | $34.3M | $5.2M | +17.96% |
| Q4 2023 | 2023-12-31 | $37.4M | $4.0M | +11.96% |
| Q3 2023 | 2023-09-30 | $33.4M | $3.0M | +9.80% |
| Q2 2023 | 2023-06-30 | $32.4M | $2.9M | +9.97% |
| Q1 2023 | 2023-03-31 | $29.1M | −$1.2M | −3.87% |
| Q4 2022 | 2022-12-31 | $33.4M | $375,000 | +1.14% |
| Q3 2022 | 2022-09-30 | $30.4M | −$430,000 | −1.39% |
| Q2 2022 | 2022-06-30 | $29.5M | $1.5M | +5.51% |
| Q1 2022 | 2022-03-31 | $30.3M | $8.3M | +37.88% |
| Q4 2021 | 2021-12-31 | $33.0M | $13.6M | +69.75% |
| Q3 2021 | 2021-09-30 | $30.8M | $12.7M | +69.95% |
| Q2 2021 | 2021-06-30 | $27.9M | $16.5M | +144.16% |
| Q1 2021 | 2021-03-31 | $22.0M | $12.2M | +125.60% |
| Q4 2020 | 2020-12-31 | $19.4M | — | — |
| Q3 2020 | 2020-09-30 | $18.1M | $11.3M | +163.57% |
| Q2 2020 | 2020-06-30 | $11.4M | — | — |
| Q1 2020 | 2020-03-31 | $9.7M | — | — |
| Q3 2019 | 2019-09-30 | $6.9M | — | — |
Prelude Therapeutics operating expenses trends
Over the last five fiscal years, Prelude Therapeutics's operating expenses increased from $58.8M to $116.7M, a change of $57.9M. The latest reported quarter, Q2 2026, shows $21.2M.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Prelude Therapeutics source filings ↗Community posts
Prelude wins FDA clearance to begin testing a new breast-cancer candidate
Prelude Therapeutics ($PRLD) received FDA clearance of its investigational-new-drug application for PRT13722, an oral KAT6A-selective degrader being developed for hormone-receptor-positive, HER2-negative breast cancer. The company expects t ...